Issue 1 JANUARY 2019

The Veeda Newsletter


Indian pharma industry records 9.4% growth in 2018, dispels GST gloom

The domestic pharmaceutical industry bounced back to a nearly double-digit year-on-year growth in 2018 (9.4 per cent), after falling to an eight-year low (5.5 per cent) in the previous year.
Read more:

Kaleo, maker of $4,100 overdose antidote, authorizes a generic version for just $178

The company announced Wednesday it has authorized its subsidiary IJ Therapeutics to produce a largely identical version of its automated naloxone injector for a retail price of $178 for a kit, which, like the $4,100 brand-name version, contains two doses.
Read more :

Gates Foundation, Bristol-Myers Join $27M Funding for Vedanta Bio

Vedanta’s experimental treatments are compositions of live bacteria that the Cambridge, MA, company says trigger a targeted immune response.
Read more :

Outlook 2019: Pharma looks medically fit for double-digit growth after years of suffering

Indian pharma companies have been going through a tough phase for the past couple of years due to significant competitive intensity and pricing pressure in the US (the largest market) and regulatory hurdles in India in terms of demonetization, GST implementation and lower prices.
Read more at:

How Takeda's $62 Billion Shire Deal Reshapes Pharma World

The rapidly changing global pharmaceutical landscape reached another milestone Tuesday as Takeda Pharmaceutical Co. completed its $62 billion acquisition of Shire Plc.
Read more :
Contact Us